Sustained-release oral dalfampridine (DrugBank: Dalfampridine)
5 diseases| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
|---|---|---|
| 3 | 脊髄性筋萎縮症 | 0 |
| 4 | 原発性側索硬化症 | 0 |
| 6 | パーキンソン病 | 0 |
| 13 | 多発性硬化症/視神経脊髄炎 | 1 |
| 14 | 慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー | 0 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02259361 (ClinicalTrials.gov) | November 2014 | 1/10/2014 | Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS | Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study | Multiple Sclerosis | Drug: Sustained-release oral dalfampridine;Drug: Placebo | Sheba Medical Center | NULL | Not yet recruiting | 18 Years | 70 Years | Both | 30 | Phase 4 | Israel |